Evidence map›Paper›PMID 26890736›Full record

Trial reportJournal of Alzheimer's disease : JAD2016

Metformin in Amnestic Mild Cognitive Impairment: Results of a Pilot Randomized Placebo Controlled Clinical Trial.

José A Luchsinger, Thania Perez, Helena Chang, Pankaj Mehta, Jason Steffener, Gnanavalli Pradabhan, Masanori Ichise, Jennifer Manly, Davangere P Devanand, Emilia Bagiella

Registry-linked trialAbstract readRandomized Controlled Trial
PubMed Full text at PMC Publisher
In one paragraph

Trial report in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00620191 (Metformin in the Prevention of Alzheimer's Disease), which is not on this map. Cited by 163 papers, 9 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
163citing papers in PubMed, 9 pooled it
11.3field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT00620191 phase2completednot on this map

Metformin in the Prevention of Alzheimer's Disease

TypeinterventionalSponsorColumbia UniversityRan2008 to 2012Enrolled80ConditionsMild Cognitive ImpairmentArmsMetformin, Placebo
3 · Its place in the literature

Who cites it

163 citing papers in PubMed, 9 syntheses or guidelines pooled it, 275 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Pooled it
  8. Pooled it
  9. Pooled it
  10. Effects of the SGLT2 inhibitor dapagliflozin in early Alzheimer's disease: A randomized controlled trial.Alzheimer's & dementia : the journal of the Alzheimer's Association · 2025
    Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Article
  16. Review
  17. Review
  18. Article
  19. Review
  20. Article

103 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 5 institutions in 1 country.

José A LuchsingerDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Thania PerezDepartment of Medicine, Columbia University Medical Center, New York, NY, USA.
Helena ChangDepartment of Statistics, Mt. Sinai Medical Center, New York, NY, USA.
Pankaj MehtaNew York Institute for Basic Research, Staten Island, NY, USA.
Jason SteffenerGertrude H. Sergievsky Center, Columbia University, New York, NY, USA.
Gnanavalli PradabhanDepartment of Psychiatry, Columbia University Medical Center, New York, NY, USA.
Masanori IchiseDivision of Geriatric Psychiatry, New York State Psychiatric Institute, New York, NY, USA.
Jennifer ManlyGertrude H. Sergievsky Center, Columbia University, New York, NY, USA.
Davangere P DevanandDepartment of Psychiatry, Columbia University Medical Center, New York, NY, USA.
Emilia BagiellaDepartment of Statistics, Mt. Sinai Medical Center, New York, NY, USA.
Columbia University Irving Medical Center · USColumbia University · USMount Sinai Hospital · USHudson Institute · USNew York State Psychiatric Institute

Funding

CTSA INFRASTRUCTURE FOR PEDIATRIC RESEARCHUL1RR024156 · NCRR · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2006 to 2011
$53.0M
Clinical and Translational Science AwardUL1TR000040 · NCATS · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI GINSBERG, HENRY N · 2012 to 2015
$26.2M
Pilot Trial of Metformin in Amnestic MCIR01AG026413 · NIA · COLUMBIA UNIVERSITY HEALTH SCIENCES · PI LUCHSINGER, JOSE ALEJANDRO · 2008 to 2010
$1.7M
NCATS NIH HHS UL1 TR000040NCRR NIH HHS UL1 RR024156NIA NIH HHS R01 AG026413
6 · The paper itself

Abstract

Diabetes and hyperinsulinemia may be risk factors for Alzheimer's disease (AD). We conducted a pilot study of metformin, a medication efficacious in treating and preventing diabetes while reducing hyperinsulinemia, among persons with amnestic mild cognitive impairment (aMCI) with the goal of collecting preliminary data on feasibility, safety, and efficacy. Participants were 80 men and women aged 55 to 90 years with aMCI, overweight or obese, without treated diabetes. We randomized participants to metformin 1000 mg twice a day or matching placebo for 12 months. The co-primary clinical outcomes were changes from baseline to 12 months in total recall of the Selective Reminding Test (SRT) and the score of the Alzheimer's Disease Assessment Scale-cognitive subscale (ADAS-cog). The secondary outcome was change in relative glucose uptake in the posterior cingulate-precuneus in brain fluorodeoxyglucose positron emission tomography. Change in plasma Aβ42 was an exploratory outcome. The mean age of participants was 65 years. Fifty percent of participants were women. The only baseline variable that was different between the arms was the ADAS-Cog. Metformin could not be tolerated by 7.5% of participants; 15% tolerated 500 mg/day, 35% tolerated 1000 mg/day, 32.5% tolerated 1500 mg/day, and only 10% tolerated the maximum dose. There were no serious adverse events related to metformin. The 7.5% of persons who did not tolerate metformin reported gastrointestinal symptoms. After adjusting for baseline ADAS-cog, changes in total recall of the SRT favored the metformin group (9.7±8.5 versus 5.3±8.5; p = 0.02). Differences for other outcomes were not significant. A larger trial seems warranted to evaluate the efficacy and cognitive safety of metformin in prodromal AD.

Indexed as

AgedAged, 80 and overAmyloid beta-PeptidesBrainCognitive DysfunctionDouble-Blind MethodFemaleFollow-Up StudiesGlucoseHumansMaleMetforminMiddle AgedNootropic AgentsOverweightPeptide FragmentsAmyloid beta-Peptidesamyloid beta-protein (1-42)GlucoseMetforminNootropic AgentsPeptide FragmentsAmnestic mild cognitive impairmentinsulinmemorymetforminrandomized clinical trial

Identifiers

PMID26890736
PMCPMC5079271
OpenAlexW2315843281

What Socratic holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.